Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

NEXT STORY
Medtronic Launches Efficio™ Software to Help Clinicians Efficiently Manage Targeted Drug Delivery Therapy with SynchroMed™ II
PREV STORY
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America

BAGNEUX, France, Jan. 26, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: ...

author_avatar
NASDAQ Market News

Aptevo Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

SEATTLE, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company ...

author_avatar
NASDAQ Market News

Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients

Completed Phase 1 trial establishes Oral KORSUVA tablet strengths for treatment of CKD-associated pruritusSTAMFORD, ...

author_avatar
NASDAQ Market News